This is normal physiology reaching a new equilibrium
Many insurers do not cover GLP-1 drugs for weight management unless a patient also has an obesity-related condition, such as heart disease, MASH or sleep apnea
In addition, a study using LPS-exposed RAW264.7 macrophages and a DSS-triggered colitis murine model demonstrated that GLP-1 attenuates inflammatory responses by inhibiting the phosphorylation process of AKT/NF-B and MAPK signal-transducing molecules under in vitro and in vivo circumstances, respectively [219]
Under certain conditions, cells can express PCSK1 and produce active GLP-1, but the mechanisms regulating cell PCSK1 expression are poorly defined
While GLP-1 drugs can result in 15-25% total body weight loss, surgery often achieves 25-35% or more, with higher rates of long-term maintenance and remission of related diseases
Comparative Analysis of Peptide Sources 6